Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines

BJ Vilner, CS John, WD Bowen - Cancer research, 1995 - AACR
Thirteen tumor-derived cell lines of human and nonhuman origin and from various tissues
were examined for the presence and density of sigma-1 and sigma-2 receptors. Sigma-1 …

FDA approval summary: mylotarg for treatment of patients with relapsed or refractory CD33‐positive acute myeloid leukemia

KJ Norsworthy, CW Ko, JE Lee, J Liu, CS John… - The …, 2018 - academic.oup.com
Gemtuzumab ozogamicin (GO) 3 mg/m 2 days 1, 4, and 7 is an active regimen for induction
of remission when used to treat patients with relapsed or refractory CD33‐positive acute …

Targeting Sigma Receptor-binding Benzamides as in Vivo Diagnostic and Therapeutic Agents for Human Prostate Tumors

CS John, BJ Vilner, BC Geyer, T Moody, WD Bowen - Cancer research, 1999 - AACR
Sigma receptors are known to be expressed in a variety of human tumor cells, including
breast, neural, and melanoma tumors. A very high density (1.0–1.5 million receptors/cell) of …

Synthesis and Characterization of [125I]-N-(N-Benzylpiperidin-4-yl)-4-iodobenzamide, a New. sigma. Receptor Radiopharmaceutical: High-Affinity Binding to MCF-7 …

CS John, BJ Vilner, WD Bowen - Journal of medicinal chemistry, 1994 - ACS Publications
4-IBP 1.70±0.44 25.2±1.28 382±39> 100 000> 100 000 3-IBP 3.02±1.06 84.6±2.5 24.8±0.02>
100000> 100 000 2-IBP 1.64±0.15 29.6±0.49 63.4±10.8> 100 000> 100 000 or hydrogen …

Sigma receptors are expressed in human non-small cell lung carcinoma

CS John, WD Bowen, VM Varma, JG McAfee… - Life sciences, 1995 - Elsevier
N-(2-piperidinoethyl)4-iodobenzamide), IPAB, was used to characterize sigma receptors in
non-small cell lung cancer (NSCLC) cell lines. IPAB bound with high affinity to large cell …

Synthesis and Pharmacological Characterization of 4-[125I]-N-(N-Benzylpiperidin-4-yl)-4-iodobenzamide: A High Affinity σ Receptor Ligand for Potential Imaging of …

CS John, BJ Vilner, ME Gulden, SMN Efange… - Cancer research, 1995 - AACR
The synthesis of [ 125 I]-N-(N-benzylpiperidin-4-yl)-4-iodobenzamide (4-[ 125 I]BP), a novel
radiopharmaceutical that possess high affinity for both σ-1 and σ-2 receptor subtypes, and its …

Phase-0/microdosing studies using PET, AMS, and LC-MS/MS: a range of study methodologies and conduct considerations. Accelerating development of novel …

T Burt, CS John, JL Ruckle… - Expert Opinion on Drug …, 2017 - Taylor & Francis
Full article: Phase-0/microdosing studies using PET, AMS, and LC-MS/MS: a range of study
methodologies and conduct considerations. Accelerating development of novel …

Sigma receptor scintigraphy with N-[2-(1′-piperidinyl) ethyl]-3-123I-iodo-4-methoxybenzamide of patients with suspected primary breast cancer: first clinical results

V Caveliers, H Everaert, CS John… - Journal of Nuclear …, 2002 - Soc Nuclear Med
The aim of this study was to investigate the potential of a new iodobenzamide, N-[2-(1′-piperidinyl)ethyl]-3-
123 I-iodo-4-methoxybenzamide (P- 123 I-MBA), to visualize primary breast …

Synthesis, in vitro binding, and tissue distribution of radioiodinated 2-[125I] N-(N-benzylpiperidin-4-yl)-2-iodo benzamide, 2-[125I] BP: A potential σ receptor marker for …

CS John, ME Gulden, J Li, WD Bowen… - Nuclear medicine and …, 1998 - Elsevier
The preclinical evaluation of a σ receptor–specific radiopharmaceutical that binds to human
prostate tumor cells with a high affinity is described. We have synthesized and …

Synthesis, in vitro pharmacologic characterization, and preclinical evaluation of N-[2-(1′-piperidinyl) ethyl]-3-[125I] iodo-4-methoxybenzamide (P [125I] MBA) for …

CS John, WD Bowen, SJ Fisher, BB Lim… - Nuclear medicine and …, 1999 - Elsevier
The goal of this study was to investigate the potential use of a radioiodinated benzamide, N-[2-(1′-piperidinyl)ethyl]-3-iodo[
125 I]-4-methoxybenzamide (P[ 125 I]MBA), a sigma …